Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program

Fizazi, 2012, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 13, 983, 10.1016/S1470-2045(12)70379-0 Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506 de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X Parker, 2013, Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 369, 213, 10.1056/NEJMoa1213755 Rathkopf, 2014, Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302), Eur Urol, 66, 815, 10.1016/j.eururo.2014.02.056 Templeton, 2013, Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials, Ann Oncol, 24, 2972, 10.1093/annonc/mdt397 van Boxtel, 2008 Caffo, 2015, Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme, BJU Int, 115, 764, 10.1111/bju.12857 Clayton, 2014, A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer, Can Urol Assoc J, 8, E583, 10.5489/cuaj.1891 Houede, 2015, Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France, BMC Cancer, 15, 222, 10.1186/s12885-015-1257-2 http://www.mskcc.org/nomograms/prostate/psa-doubling-time [accessed between 02.09.13. and 03.12.14.]. Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, published June 14, 2010. United States Department of Health and Human Services. http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Sternberg, 2014, Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial, Lancet Oncol, 15, 1263, 10.1016/S1470-2045(14)70417-6 Azad, 2015, Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status, Eur Urol, 67, 441, 10.1016/j.eururo.2014.01.030 Gurwitz, 2003, Incidence and preventability of adverse drug events among older persons in the ambulatory setting, J Am Med Assoc, 289, 1107, 10.1001/jama.289.9.1107